PMEF
EDIT icon

Point72 Middle East FZE’s Editas Medicine EDIT Stock Holding History

Point72 Middle East FZE’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-119,125
Closed -$1.21M – 418
2023
Q4 		$1.21M Buy
119,125
+103,003
+639% +$904K 0.04% 543
2023
Q3 		$126K Sell
16,122
-32,393
-67% -$278K ﹤0.01% 1104
2023
Q2 		$399K Buy
48,515
+23,653
+95% +$206K 0.01% 843
2023
Q1 		$180K Buy
+24,862
New +$221K 0.01% 971

Other funds holding EDIT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Point72 Middle East FZE's EDIT Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Editas Medicine (EDIT) in Q1 2024, closing a stake of 119,125 shares — an estimated $1.21M sold.

Point72 Middle East FZE first reported a position in EDIT in Q1 2023 and held it in 4 quarters. The position peaked at $1.21M in Q4 2023. 225 funds tracked by Wall St. Rank hold EDIT as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Editas Medicine position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 119,125 Editas Medicine shares in Q1 2024, an estimated $1.21M.
  • Point72 Middle East FZE first reported a position in Editas Medicine in Q1 2023 and held it in 4 quarters.
  • Point72 Middle East FZE's Editas Medicine position peaked at $1.21M in Q4 2023.
  • 225 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.